FDA Fast-Tracks Tolebrutinib Review for Non-Relapsing Secondary Progressive MS Treatment

The US Food and Drug Administration (FDA) is evaluating under priority review the regulatory submission of tolebrutinib to treat non-relapsing secondary pr...

March 26, 2025 | Wednesday | News
Nxera Pharma’s Partner Tempero Bio Launches Phase 2 Trial of TMP-301 for Alcohol Use Disorder

Nxera Pharma Co., Ltd. announces that its partner Tempero Bio, Inc. has initiated a Phase 2 trial of TMP-301, a potent, selective and orally available mGlu...

March 25, 2025 | Tuesday | News
Shanghai Junshi Biosciences' Toripalimab Receives NMPA Approval for First-Line Treatment of Metastatic Liver Cancer

Shanghai Junshi Biosciences Co., Ltd, a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

March 24, 2025 | Monday | News
Rhythm Pharmaceuticals Reacquires Rights to IMCIVREE® (setmelanotide) in China, Hong Kong, and Macau

 Rhythm Pharmaceuticals, Inc., a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neur...

March 24, 2025 | Monday | News
Terumo Neuro Celebrates 15th Anniversary of WEB™ Aneurysm Embolization System, Revolutionizing Aneurysm Treatment

Terumo Neuro, a global leader in neurovascular innovation and a wholly-owned subsidiary of Terumo Corporation, proudly celebrates the 15th anniversary of t...

March 24, 2025 | Monday | News
Menarini Group and Stemline Collaborate with VisualDx to Enhance Early Detection of BPDCN Using AI/ML Technology

Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned s...

March 24, 2025 | Monday | News
Johnson & Johnson’s TREMFYA® Approved by FDA as First Dual-Acting IL-23 Inhibitor for Crohn’s Disease

Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab), the first and only IL-23...

March 24, 2025 | Monday | News
Novartis Wins FDA Approval for Fabhalta®, First Oral Therapy for C3G

Novartis announced that oral Fabhalta® (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with ...

March 24, 2025 | Monday | News
Paratek Pharmaceuticals to Acquire Optinose for Up to $330 Million, Expanding Portfolio with XHANCE®

Paratek Pharmaceuticals and Optinose, Inc. announced they have entered into a definitive merger agreement under which Paratek will acquire Optinose, includ...

March 21, 2025 | Friday | News
Porton Advanced Partners with Eureka Therapeutics to Accelerate T-Cell Therapy Development

Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleas...

March 21, 2025 | Friday | News
FDA Clears Altesa BioSciences' IND for Vapendavir to Treat Rhinovirus Infections in COPD Patients

Altesa BioSciences, Inc., a clinical-stage pharmaceutical company dedicated to developing new treatments for viral infections in vulnerable populations, an...

March 21, 2025 | Friday | News
Cumberland Pharmaceuticals' Phase 2 FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Conference

Cumberland Pharmaceuticals Inc. a specialty pharmaceutical company with development efforts focused on rare diseases, announced that results from its Phase...

March 21, 2025 | Friday | News
bioLytical Launches INSTI® Multiplex HIV-1/2 Syphilis Antibody Test in Australia for Rapid Diagnosis

RICHMOND, British Columbia, bioLytical Laboratories Inc. (“bioLytical”), a global leader in rapid infectious disease diagnostics, announces the...

March 20, 2025 | Thursday | News
Moon Surgical Secures FDA Clearance for ScoPilot, First AI-Powered Intraoperative Tool

Moon Surgical, a French-American pioneer in surgical innovation, announced the United States Food and Drug Administration (FDA) clearance for ScoPilot. Ena...

March 20, 2025 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close